New Releases from NCBI BookshelfGlofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments .Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments .